Day – Page 19 – Communicable Diseases Research

Clinical characteristics of SARS-CoV-2 pneumonia diagnosed in a primary care practice in Madrid (Spain)

마드리드(스페인)의 1차 진료에서 진단된 SARS-CoV-2 폐렴의 임상적 특징

Observational Study

Published on 2021-04-292022-09-01
Journal: BMC Family Practice [Category] MERS, SARS, 임상, 진단,

Natural tannin extracts supplementation for COVID-19 patients (TanCOVID): a structured summary of a study protocol for a randomized controlled trial

COVID-19 환자를 위한 천연 탄닌 추출물 보충제(TanCOVID): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-04-282022-09-10
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] 1:1 24 hour 24 hours addition Administered administration affected age All trial participants all-cause mortality Alpha alpha error Antibiotic therapy antipyretics assigned assisted ventilation Azithromycin B12 blinded Blinding branch Buenos Aire Buenos Aires can not Chestnut tannins Clinical symptoms clinical trial closure cognitive computer-generated random numbering conditions Consent control group COVID-19 COVID-19 patient criteria cytokine Cytokines Day Decline decrease defined Definition Department described diagnosis of SARS-CoV-2 dietary supplement difference disease dissemination dose double-blind Efficacy element eligibility eligible enrolled Enrollment enrolment epidemiological evaluate excluded fecal Final first dose first visit Gender gut microbiota Hospital de Clínica Hospital de Clínicas Hospital de Clinicas Jose de San Martin hospital discharge Hydroxychloroquine hypersensitivity ICU impaired consciousness increase in indicated Infection Infectious disease Infectious diseases Inflammation inflammatory mediator Inflammatory mediators Informed consent intestinal intestinal permeability invasive ventilation lactating Level Lopinavir mean difference measure mechanical ventilation mediators microbiota modifications molecular natural non-invasive ventilation number objective Older outcome parallel-group parameter participant Participation Patient patients per day Placebo placebo-controlled platform Potential power power of 80% protocol Quebracho tannins randomization Randomized Randomized controlled trial Randomly Real-time PCR receive recruited recruitment Registered Research Ritonavir Sample size SARS-COV-2 infection SARS-CoV2 screened secondary secondary outcome measures severity Standard therapy standard treatment status study participant Study protocol study randomization submitted supplementary material supply tannin tannins therapy time Time frame took place Treatment treatment allocation Trial trial participant Trial registration undergo university Ventilation website
[DOI] 10.1186/s13063-021-05281-x PMC 바로가기 [Article Type] Letter

Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial

무증상 및 경증 COVID-19 환자에 대한 nelfinavir의 효능 및 안전성: 다기관, 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-04-282022-09-10
Journal: Trials [Category] SARS, 임상, 치료기술,

[키워드] 1:1 Administered administration adverse event adverse events age all-cause mortality ALT Analysis anticipated Antigen antiviral efficacy AST Asymptomatic asymptomatic patients blinded blinded outcome assessment Blinding blood glucose body temperature both group both groups capture caused childbearing potential clearance clinical Clinical efficacy clinical examinations Clinical symptoms clinical trial clinical trials comparator Patients condition Consent contraceptive method Controlled clinical trial cough COVID-19 creatinine creatinine clearance dataset Day defervescence diabete diabetes diarrhea discretion dissemination distribution drug element enrolled enrolment evaluate event exclusion criteria exploratory Factor female patient Fever Frequency Glucose group hazard ratio Hemophiliac Hemorrhagic history HIV infection hospital hypersensitivity incidence incidence rate Inclusion inclusion and exclusion criteria inclusion criteria Infection Informed consent initial investigator investigator-initiated investigators Japan Japanese LAMP limit log-rank test male Mild mild COVID-19 patient Mild disease mixed-effects model multicenter Nasopharyngeal swab Negative conversion Negative PCR nelfinavir null hypothesis number objective Open-label outcome oxygen Oxygen administration p value parallel group parameter participant Patient patients with asymptomatic PCR PCR test Pneumonia power Pregnancy primary endpoint Primary outcome principal investigator Probability probability distribution protocol random randomization Randomized Randomized controlled trial Registered registry reported required respiratory tract rifampicin room air safety endpoint Saliva saliva samples Sample size SARS-CoV-2 SARS-CoV-2 vaccination secondary efficacy endpoint serious complication serum creatinine severity specimen Standard status study period Study protocol supplementary material survival survival function Symptom symptomatic symptomatic COVID-19 Symptomatic treatment the log-rank test Three times daily Treatment treatment for HIV treatment period Trial Trial registration two-sided Unsuitable Viral viral dynamics Viral load virus was determined website Withdrawal withdrawal of consent
[DOI] 10.1186/s13063-021-05282-w PMC 바로가기 [Article Type] Letter

Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials

Clinical Trial

Published on 2021-04-282022-10-05
Journal: Chinese medical journal [Category] SARS, 임상,

[키워드] acute respiratory syndrome administration Adults adverse event anti-receptor-binding domain antibody Chinese clinical trial conducted coronavirus Day dose doses double-blind effective Efficacy Endpoint enrolled healthy immune response immunogenicity Immunoglobulin inactivated Inactivated vaccine incidence induce Infection intensity morbidity and mortality neutralization nine participant Phase 1 phase 1 trial phase 2 trial Phase 3 Placebo placebo-controlled placebo-controlled trial primary immunogenicity proportion Randomized receive receiving regimen regimens reported robust Safe SARS-CoV-2 SARS-CoV-2 vaccine second dose serious AE Seroconversion Seven Support treatment groups Trial Vaccine vaccine doses Vaccines
[DOI] 10.1097/CM9.0000000000001573 PMC 바로가기 [Article Type] Clinical Trial

High Dose Intravenous Vitamin C for Preventing The Disease Aggravation of Moderate COVID-19 Pneumonia. A Retrospective Propensity Matched Before-After Study

Pharmacology

Published on 2021-04-222022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] 1:1 activated addition Admission age and gender aggravation C-reactive protein CD4 Clinical course clinical study coagulation function coagulation indicators control group Coronavirus disease 2019 country COVID-19 COVID-19 patient D-dimer Day disease disease aggravation early stage effective HDIVC High-dose immune function improvement Inflammatory response intravenous Intravenous injection Matched moderate Moderate COVID-19 Occurrence outcome pandemic Patient patients patients with moderate Pneumonia Preventing Primary outcomes protocol Randomized controlled trial required retrospective risk significant difference SIRS syndrome systemic inflammatory response T cell therapy treated Treatment two group Vitamin Vitamin C
[DOI] 10.3389/fphar.2021.638556 PMC 바로가기 [Article Type] Pharmacology

A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial

SARS-CoV-2 백신(비활성화, Vero 세포)의 효능과 안전성을 평가하기 위한 무작위 이중 맹검 위약 대조 임상 3상 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-04-132022-09-10
Journal: Trials [Category] MERS, SARS, 비임상, 임상, 치료기술,

[키워드] 1:1 24 hour 24 hours 95% confidence interval Activation Active surveillance administration Administrative Personnel Adverse adverse event adverse events Adverse reaction Adverse reactions African green monkey age Algorithm Aluminium aluminium hydroxide anaphylaxis Antibody test Antibody titer Antigen Arm asplenia assigned assumed assumption Autoimmune baseline bleeding disorders Blinding blood product blood products blood sample Blood samples breastfeeding women breath carried Cell culture China chloride Clinical efficacy clinical trial code Cohort cohorts comparator consent form cooperation Corticosteroid Corticosteroids COVID-19 COVID-19 cases COVID-19 disease COVID-19 symptoms COVID-19 test criteria Critical CRO Data and Safety Monitoring Board Day development diary dihydrogen DIHYDROGEN PHOSPHATE disease disodium disodium hydrogen phosphate dissemination dose dose of vaccination double blind double-blind double-blind study Efficacy Efficacy and safety element eligible Endpoint enrolled enrolment ethics committee evaluate event excluded exclusion criteria expected Follow-up follow-up period Frequency Gender genders green monkey group groups healthcare Healthcare professional healthcare professionals higher risk HIV infection hospital Hospitalization hydrogen Hydrogen phosphate hydroxide hypersensitivity identity IgG level IgG levels IgG test immunogenicity Immunoglobulin immunoglobulins immunosuppressive immunosuppressive therapy inactivated Inactivated Vaccines incidence incidence rate include Inclusion individual information informed consent form initiated Interactive Web Response System intramuscular dose investigator IWRS IWRS system kidney knowledge Local local reactions management medical doctors medical emergency Ministry of Health mortality rates neutralizing antibody Neutralizing antibody titer Novel coronavirus number Nurses objective Omega Other participant PCR PCR positivity performed Phase III Clinical Trial phosphate Placebo placebo group placebo-controlled positive pregnancy test pregnant preparation primary efficacy endpoint professional proportion protocol randomised randomised controlled trial randomised placebo controlled trial randomization Randomized Randomly Reactions receive recorded regimens Registration reported response risk risk of infection RT-PCR RT-PCR test RT-PCR tests Safety Monitoring Board Sample size SARS-CoV-2 vaccine SARS-CoV-2 virus screened second dose secondary Secondary objectives Serious Adverse Event Serious Adverse Events seroconversion rate Seropositivity severity severity of COVID-19 shown Sinovac sodium Sodium chloride sodium dihydrogen phosphate Sponsor status study group Study protocol subject subject’ supplementary material Symptom symptomatic symptomatic case symptomatic cases System systemic adverse reaction the ethics committee the timing the vaccine therapy Treatment treatment arm Trial Turkey two-sided vaccinated groups vaccination Vaccine Vero Vero Cell Web website width with COVID-19 within 6 months
[DOI] 10.1186/s13063-021-05180-1 PMC 바로가기 [Article Type] Letter

Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial

경증 또는 중등도의 COVID-19 폐렴으로 입원한 환자를 위한 염증 신호 억제제(MATIS)의 다군 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-04-122022-09-10
Journal: Trials [Category] 임상,

[키워드] 24 hours accounted Administered age agreement All participants Allergic reactions approved baseline blind blinded Blinding block Breastfeeding Caregivers cell proliferation childbearing potential clinical clinical outcomes clinically suspected college comparator completion Compliance Concomitant medication Contraception Controlled trial coronavirus COVID-19 COVID-19 disease COVID-19 pneumonia CPAP CRP Data monitoring committee Day death defined Desaturation determine diagnosed disease disease severity dissemination dose drug ECMO effective Efficacy element English enrolment exclusion experimental arm experimental intervention facemask FOS fostamatinib generate GRADE grade 3 Graft graft-versus-host-disease hepatic dysfunction hospital Hospital admission Hospital stay hospitalisation hospitalised patient Hospitalised patients Immune thrombocytopenia Imperial College Healthcare NHS Trust incidence information Informed consent inhibitor Inpatient Inpatients Intervention invasive Invasive mechanical ventilation invasive ventilation investigational agent investigator JAK1 JAK2 janus kinase Kinase inhibitor kinases Laboratory male participants MATIS Mild minimum moderate Moderate COVID-19 moderate to severe Modification multi-arm myelofibrosis nasal oxygen NHS Non-invasive non-invasive ventilation number objective Obstructive obstructive sleep apnoea opinion Ordinal Scale outcome oxygen Pairwise comparison pandemic parallel-group participant Patient Pneumonia polycythaemia vera principal investigator product progression promise proportion protocol random randomisation randomised randomised controlled trial receiving recruit recruited reduce reduce mortality reducing renal impairment renal replacement therapy replacement therapy required Requirement ruxolitinib Sample size sample size calculation Sample size calculations SARS-CoV2 infection scale Secondary objectives selective sequence severe allergic reaction Severe COVID-19 pneumonia severity severity of COVID-19 sexual intercourse signal sleep apnoea Sperm sperm donation spleen Splenomegaly Stage stage 2 Standard Standard of care statistical analysis status Stratification study drug Study protocol supplementary material Symptom systemic inflammation the WHO therapy thrombocytopenia translation Treatment Trial Trial registration Trust tyrosine tyrosine kinase inhibitor Venous Thromboembolism verbal website WHO with COVID-19
[DOI] 10.1186/s13063-021-05190-z PMC 바로가기 [Article Type] Letter

Prevalence and Persistent Shedding of Fecal SARS-CoV-2 RNA in Patients With COVID-19 Infection: A Systematic Review and Meta-analysis

COVID-19 감염 환자에서 대변 SARS-CoV-2 RNA의 유병률 및 지속적인 배출: 체계적인 검토 및 메타 분석

Meta-Analysis

Published on 2021-04-092022-09-11
Journal: Clinical and Translational Gastroenterology [Category] SARS, 치료기술,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus Anal Chinese Confirmed COVID-19 infection coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection COVID-19 patient criteria database Day detectable diarrhea evaluate fecal feces GI symptom GI symptoms increased risk Infection Infrastructure mean difference Meta-analysis Odds ratio Patient patients with COVID-19 performed persistent Prevalence proportion rectal respiratory sample Respiratory samples review RNA SARS-CoV-2 SARS-CoV-2 RNA searched shedding Systemic review the patient Web of Science
[DOI] 10.14309/ctg.0000000000000343 PMC 바로가기 [Article Type] Meta-Analysis

Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study

입원하지 않은 경증에서 중등도의 COVID-19 환자에서 장내 미생물군유전체 조절의 자연사 및 영향을 평가하기 위한 가상화된 임상 연구 장내 미생물군 구조에 대한 KB109의 생리학적 효과를 평가하는 병렬 그룹 연구와 함께 무작위, 공개, 전향적 연구 및 기능: 무작위 대조 연구를 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-04-022022-09-10
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] 1:1 24 hours Ability absence addition adhere Affect age Ageusia allergy analysed Anosmia Anosmia/ageusia Antacid Antibiotics Antiviral assessment assigned Autoimmune disease Bariatric surgery baseline bilevel positive airway pressure Biomarker Biomarkers biomarkers of inflammation BiPAP Blinding blocker Blood blood sample Blood samples both groups bowel bowel resection breath Care care provider Cell change Chest chest tightness chills chronic lung disease cirrhosis clinical clinical study clinical trial Cold collected Community Comorbidity comparator Patients completion Compliance component computer Concomitant medication concomitant medications concurrent condition conducted contraindications coronavirus disease Coronavirus disease 2019 cough COVID-19 COVID-19 in patient COVID-19 symptom COVID-19 symptoms COVID-19 testing COVID-19-related symptom COVID-19-related symptoms COVID-19–related symptom COVID-19–related symptoms CPAP Cytokines D-dimer daily dose Day defined diarrhea dissemination drug duration of symptom Effect element eligible Enrollment evaluate evaluate the effect evaluated exacerbated exclusion criteria exploratory fatigue fatty Fatty acid feasible Female patients Fever fiber Follow-up follow-up period following group Gut gut microbiome gut microbiome composition gut microbiota headache Health Health care Health Care Utilization Health status healthcare Histamine history hospital Hospital admission Hospital admissions Hospitalization Hospitalized hypoxia Identifier IgM/IgG Immunity immunomodulatory immunosuppressive immunosuppressive therapy in both group include Infection Inflammation Inflammatory biomarker Inflammatory bowel disease information Informed consent inhibitors intake Interaction investigational agent irritable bowel syndrome KB109 Laboratory laboratory measures lactating library life Liver disease Lung disease magnitude malignancy management measure Measures medication medications Medicine metabolite Microbiome microbiota Mild mild to moderate Mild to moderate COVID-19 mild to moderate disease moderate Moderate COVID-19 moderate disease modulate modulation muscle pain nasal congestion neutralization assays not limited nucleic acid number objective Open-label opinion other compound other compounds outcome outcome measure Outpatient outpatients oxygen oxygen saturation Oxygen therapy Pain parallel group participant Participation Patient patient population Period Physical examination positive airway pressure Positive test Potential pre-symptomatic pregnant Primary outcome progression proportion proportions Prospective Study PROTECT protocol protocols proton pump provided pulse Pulse oximeter Quality of life Quantitative question randomisation randomised randomised controlled study randomization Randomized randomized controlled study receive recruitment reduction Registered reported response resting position risk risk of infection Sample size screened selected self-care sensitivities Sequencing serological serology shaking short-chain fatty acids Shortness of breath Sleep sleep apnea Smartphone sore throat specific biomarker specific biomarkers Spread SSC Standard Stool stratified Study design Study protocol study visit supplementary material Swab Symptom symptomatic patient Symptomatic patients Symptoms syndrome Tablet TEAEs Telemedicine telephone temperature the patient The United States therapy time Tolerability Treatment treatment-emergent adverse event undergo United States unlikely Viral Viral load water website worsening
[DOI] 10.1186/s13063-021-05157-0 PMC 바로가기 [Article Type] Letter

Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm

항-CD28 항체(TGN1412) 유발 사이토카인 폭풍 후 면역 재구성 및 임상 회복

Clinical Trial

Published on 2021-04-012022-08-31
Journal: Cancer immunology, immunotherapy : CII [Category] MERS, SARS, 바이오마커, 임상, 진단,

[키워드] adverse event adverse events antibody asymptomatic patients autoantibody Cancer immunotherapy CD28 CD4 CD8 cells clinical recovery clinical trial cognitive Cognitive deficits Concentration consequence COVID-19 cytokine Cytokine dysregulation cytokine release Cytokine release syndrome Cytokine storm Cytokines Day declined defined dendritic cell dendritic cells Depression described diagnosed dry gangrene dysregulation elevated Follow-up Gastrointestinal healthy volunteer IgE immune immune dysregulation Immune monitoring Immune-related adverse events (irAEs) immunopathology Immunotherapy infections initial irAEs irritability memory Mild-to-moderate mucosal naïve neutropenia observation one patient over Patient problem problems pruritus Psychological raynaud s phenomenon required serum cytokine serum cytokines subset suffered Symptom systemic symptoms T-cell T-cells T-regulatory cell T-regulatory cells targets TGN1412. Treatment undetectable
[DOI] 10.1007/s00262-020-02725-2 PMC 바로가기 [Article Type] Clinical Trial